NYSE · Health Care

ZOETIS INC ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
  • It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
  • In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors.
  • It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - specialty & generic?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 4 Current sample portfolio
Public mentions 1 Videos / interviews / letters
Valuation snapshot
PE 13.01 FCF 6.72% Buyback 3.25%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Polen Capital Management 3.5% $499.2M 2026-03-31
Fundsmith Terry Smith 3.6% $458.4M 2026-03-31
Sequoia Fund 4.8% $286.7M 2026-03-31
Wedgewood Partners David Rolfe 2.8% $13.4M 2026-03-31

Recent trading changes over the last 3 quarters

Net buyers 3 Last 3 13F filing periods
Net reducers 2 Last 3 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $414.0M Estimated from net added shares
Reduction amount $497.4M Estimated from net reduced shares
Net share change / base shares -6.4% -725,989 / 11,429,200
Fundsmith Terry Smith 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 25.3% 13F value change +$79.1M
13F 2025-12-31 Filed 2026-02-17
Minor increase Shares 7.9% 13F value change -$38.2M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -0.6% 13F value change -$32.4M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 2,884,831 Last 3 periods +992,728 (+34.4%) Total shares 3,877,559 Value $458.4M
Soros Fund Management George Soros 2 filing periods
13F 2025-12-31 Filed 2026-02-13
New Shares - 13F value change +$18.7M
13F 2026-03-31 Filed 2026-05-15
Sold out Shares -100.0% 13F value change -$18.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 3 periods +0 (New) Total shares 0 Value $0
Sequoia Fund 1 filing periods
13F 2026-03-31 Filed 2026-05-15
New Shares - 13F value change +$286.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 3 periods +2,425,010 (New) Total shares 2,425,010 Value $286.7M
Wedgewood Partners David Rolfe 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 3.4% 13F value change -$65,715
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -17.9% 13F value change -$5.5M
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 8.4% 13F value change +$248,186
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 123,343 Last 3 periods -9,802 (-7.9%) Total shares 113,541 Value $13.4M
Polen Capital Management 3 filing periods
13F 2025-09-30 Filed 2025-11-12
Minor reduction Shares -10.7% 13F value change -$213.4M
13F 2025-12-31 Filed 2026-02-12
Major reduction Shares -26.0% 13F value change -$400.0M
13F 2026-03-31 Filed 2026-05-14
Major reduction Shares -24.1% 13F value change -$200.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-14
Base shares 8,421,026 Last 3 periods -4,197,950 (-49.9%) Total shares 4,223,076 Value $499.2M
Bridgewater Associates Ray Dalio 2 filing periods
13F 2025-03-31 Filed 2025-05-14
New Shares - 13F value change +$23.7M
13F 2025-06-30 Filed 2025-08-13
Major reduction Shares -55.5% 13F value change -$13.7M
Settlement As of 13F 2025-06-30 · Filed 2025-08-13
Base shares 0 Last 3 periods +64,025 (New) Total shares 64,025 Value $10.0M

Recent mentions

Fundsmith Equity Fund 2025 Semi-Annual Letter

Fundsmith · Terry Smith

2025 semi-annual letter disclosed Fundsmith’s first half portfolio adjustments: began to accumulate Zoetis, Intuit, EssilorLuxottica, and sold PepsiCo and Brown-Forman.

Shareholder letter / fund letter

Mentioned by firms